Depression in Parkinson's: SSRI/SNRI vs. Pramipexole
His selegiline makes a standard SSRI a real serotonin-syndrome consideration — a dopamine agonist could treat his mood and his motor symptoms with one drug, at the cost of a very different risk profile.
W.T., a 68-year-old retired civil engineer, was diagnosed with Parkinson's disease two years ago and has been managed on levodopa/carbidopa with selegiline 5mg twice daily, added early in his course for its modest neuroprotective rationale and mild symptomatic benefit. His motor symptoms remain mild — some hand tremor, slightly slowed gait — and well-controlled on his current regimen, with no motor fluctuations or dyskinesias yet.
Over the past three months he has developed a depressive episode distinct from any prior mood history: persistent low motivation, poor sleep, and a PHQ-9 of 18, in a man his wife describes as having never struggled with mood before his diagnosis. He has no other chronic illness. Depression in Parkinson's disease is common and under-recognized, often overlapping symptomatically with the disease's own motor slowing and fatigue, but his presentation includes clearly depressive cognitive symptoms — hopelessness, guilt, loss of interest in his woodworking hobby — that go beyond what motor slowing alone would explain.
The genuine pharmacologic tension is that his existing selegiline, a selective MAO-B inhibitor, carries a real if graded interaction risk with SSRIs — serotonin syndrome has been reported with this combination, and the selegiline label lists concurrent SSRIs as contraindicated outright — but observed rates in practice are low, neurology guidance treats the combination as usable with counseling, and the risk is well below that of a nonselective MAOI. Pramipexole, a dopamine agonist, has real trial evidence for treating depression in Parkinson's disease specifically, working through a mechanism distinct from serotonergic antidepressants and potentially addressing both his mood and his motor symptoms with a single added drug — but it carries its own well-documented risk of impulse control disorders, including pathological gambling, hypersexuality, and compulsive spending, along with sedation and orthostatic hypotension, none of which his current regimen has exposed him to.
At the combined neurology-psychiatry consultation
I don't want to understate the selegiline interaction, but I also don't want to overstate it either. The label does contraindicate concurrent SSRIs, and we should say so plainly rather than skip past it — but at the 10mg daily ceiling that preserves MAO-B selectivity, observed serotonin syndrome rates with an SSRI are low, well below a nonselective MAOI, and neurology practice treats this as manageable with counseling rather than as an absolute bar. Prescribing here means prescribing against a labeled contraindication knowingly, which he should be told.
Pramipexole is genuinely appealing here specifically because it could address both his motor symptoms and his mood with one addition, and there's real trial evidence for its antidepressant effect in Parkinson's disease independent of motor improvement.
I'd want him and his wife to hear the impulse-control-disorder risk in concrete terms before we default to pramipexole for that reason alone — pathological gambling and compulsive spending aren't rare footnotes with dopamine agonists, and a patient with no psychiatric history who doesn't know to watch for this could do real financial or relational damage before anyone notices the pattern.
If his motor symptoms don't specifically need a dopamine agonist added right now, treating his depression with an SSRI and managing the selegiline interaction through patient education and dose spacing may be the lower-total-risk path, even with the interaction caveat.
Given his motor symptoms are mild and not currently undertreated, I'd lean toward sertraline with explicit serotonin syndrome education — specific symptoms to watch for, a clear same-day contact plan if they appear — over introducing pramipexole's ICD risk into a patient who hasn't been exposed to it and doesn't currently need additional motor benefit. If his motor symptoms progress later and a dopamine agonist becomes independently indicated, that's a different, better-justified point to revisit the antidepressant question.
Sertraline was started at a conservative 25mg with slow titration, selegiline was continued unchanged, and both W.T. and his wife received explicit written education on serotonin syndrome symptoms and a same-day contact number.
The combination continues, with routine follow-up watching specifically for any early interaction symptoms rather than assuming the risk has passed once titration is complete.
Pramipexole would be reconsidered at that point with its own dedicated impulse-control-disorder counseling, on genuinely stronger footing than adding it for mood benefit alone.
The team's reasoning was explicit that this decision could look different in six months — pramipexole wasn't ruled out as wrong, only as premature given where his motor symptoms and his exposure to that specific risk currently stand.